China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA) has accepted for review the market approval filing for its Category III medical device, MaiLi Extreme, a lidocaine-containing crosslinked sodium hyaluronate gel. This high-end hyaluronic acid product, which received the CE mark in June 2020, was launched in the European Union during the first half of 2021.
The inclusion of lidocaine in the gel formulation is designed to alleviate pain during hyaluronic acid injection procedures. MaiLi Extreme features the world’s first OxiFree patented manufacturing technology, which helps to preserve long molecular hyaluronic acid chains and significantly reduces the amount of crosslinking agent used in the product. With a low degree of hyaluronic acid modification, the product offers long-lasting and superior filling effects.- Flcube.com
